Scientists are getting closer to understanding the wasting and fatigue that often accompanies cancer. Treatments could be on ...

The biotech’s potential launch on the public markets would help fuel development of its clinical-stage, melanocortin-focused pipeline.

New research from the University of Oklahoma reveals a previously unknown chain of events sparking the development of cancer cachexia, a debilitating muscle-wasting condition that almost always occurs ...

Cachexia-a syndrome characterized by progressive muscle wasting-affects both humans and dogs with chronic diseases such as cancer.

Many people with cancer experience dramatic loss of muscle and fat tissue. In many cases, even the heart muscle is affected, which further weakens the body. This wasting syndrome, known as cachexia, ...

Cachexia—a syndrome characterized by progressive muscle wasting—affects both humans and dogs with chronic diseases such as ...

Cachexia is a condition in which patients affected by cancer or other chronic diseases become sick and lose weight.

Though cancer cachexia has been researched extensively, it remains challenging to understand and treat. Though cancer cachexia has been researched extensively, it remains challenging to understand and ...

Many important advances have occurred in the field of cancer cachexia over the past decade, including progress in understanding the mechanisms of CACS and the development of promising pharmacologic ...

The dietary supplement melatonin does not improve the symptoms of cachexia in patients with advanced cancer, according to a study published online February 25 in the Journal of Clinical Oncology.